ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Patterns of self-reported diarrhea in patients with cancer receiving chemotherapy.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeDiarrhea is prevalent in individuals with cancer undergoing chemotherapy and negatively affects their outcomes, treatment adherence, and survival. With the majority of patients receiving chemotherapy in an outpatient setting, treatment-related toxicities, including diarrhea, are experienced while at home, and, therefore, their prevalence, frequency, and associated distress remain largely uncaptured. This study aimed to assess the prevalence and severity of patient-reported diarrhea and the relationship between diarrhea severity and its associated distress.
methodsWe performed a secondary analysis of diarrhea severity and associated distress ratings (1-10) reported over the course of chemotherapy by individuals with various types and stages of malignancies. Symptoms were assessed daily through an automated telephone system.
resultsOut of 345 participants, 217 (62.90%) reported at least one episode of diarrhea. Of the reported diarrhea occurrences, 60.39% were classified as mild (1-3), 34.62% as moderate (4-7), and 4.99% as severe (8-10). The mean duration of mild, moderate, and severe diarrhea was 3.57, 4.84, and 1.43 days, respectively. Of all diarrhea episodes, 97.40% were reported between cycles 1 and 8, with cycle 1 having the greatest number of reported episodes. Out of these, cycle 5 had the highest average diarrhea severity (4.02) and cycle 8 the lowest (2.98). The average number of diarrhea reports per patient was 4.94 for participants in mild symptom group, 3.98 in moderate, and 1.78 in severe. A simple linear regression revealed a significant beta of 0.91 (p < 0.001) between diarrhea severity and the associated distress score.
conclusionsDiarrhea affected over 60% of study participants. Its severity was highly correlated with patient-reported distress. Clinicians need to be aware that diarrhea can significantly disrupt patients' wellbeing and make it a priority of patient education and post-treatment assessment.
Indexed as
Identifiers
39909912What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.